This distinct expression may explain subgroup differences in treatment response and suggest potential avenues for tailored therapy, such as TYMS or PARP inhibition in MSI tumors and restoration of apoptotic signaling or targeting compensatory pathways in MSS tumors. This evidence concerns the gene PARP1 and Marinesco-Sjogren syndrome.